GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (BSP:B1GN34) » Definitions » Other Current Payables

BeiGene (BSP:B1GN34) Other Current Payables : R$237 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BeiGene Other Current Payables?

BeiGene's Other Current Payables for the quarter that ended in Mar. 2024 was R$237 Mil.

BeiGene's quarterly Other Current Payables increased from Sep. 2023 (R$212 Mil) to Dec. 2023 (R$271 Mil) but then declined from Dec. 2023 (R$271 Mil) to Mar. 2024 (R$237 Mil).

BeiGene's annual Other Current Payables increased from Dec. 2021 (R$154 Mil) to Dec. 2022 (R$162 Mil) and increased from Dec. 2022 (R$162 Mil) to Dec. 2023 (R$271 Mil).


BeiGene Other Current Payables Historical Data

The historical data trend for BeiGene's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Other Current Payables Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.31 19.03 154.42 162.46 271.29

BeiGene Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 164.58 187.06 212.34 271.29 236.64

BeiGene Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


BeiGene Other Current Payables Related Terms

Thank you for viewing the detailed overview of BeiGene's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene (BSP:B1GN34) Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (BSP:B1GN34) Headlines

No Headlines